Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 4, Issue 2, 2012, Pages

  Weggen, Sascha ^a   Beher, Dirk ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b MERCK SERONO S A   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GAMMA SECRETASE; PRESENILIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; AUTOSOMAL DOMINANT DISORDER; BRAIN METABOLISM; DISEASE COURSE; FAMILIAL DISEASE; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VASCULAR AMYLOIDOSIS;

EID: 84858720343     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt107     Document Type: Review

References (128)

1. 2011 Alzheimer's disease facts and figures. Alzheimer Association, Alzheimers Dement 2011 7 208 244 21414557
2. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. De Strooper B, Annaert W, Annu Rev Cell Dev Biol 2010 26 235 260 10.1146/annurev-cellbio-100109-104117 20604710
3. Alzheimer's disease: genes, proteins, and therapy. Selkoe DJ, Physiol Rev 2001 81 741 766 11274343 (Pubitemid 32267077)
4. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C, Alzheimers Res Ther 2011 3 1 21211070
5. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Glenner GG, Wong CW, Biochem Biophys Res Commun 1984 120 885 890 10.1016/S0006-291X(84)80190-4 6375662 (Pubitemid 14104991)
6. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B, Nature 1987 325 733 736 10.1038/325733a0 2881207 (Pubitemid 17054046)
7. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K, Proc Natl Acad Sci USA 1985 82 4245 4249 10.1073/pnas.82.12.4245 3159021 (Pubitemid 15053619)
8. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, Myers RH, Feldman RG, Pollen D, Drachman D, Science 1987 235 885 890 10.1126/science.2880399 2880399 (Pubitemid 17019126)
9. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL, Science 1987 235 880 884 10.1126/science.2949367 2949367 (Pubitemid 17019125)
10. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GT, Luyendijk W, Frangione B, Science 1990 248 1124 1126 10.1126/science.2111584 2111584
11. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Nature 1991 349 704 706 10.1038/349704a0 1671712 (Pubitemid 21912142)
12. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Murrell J, Farlow M, Ghetti B, Benson MD, Science 1991 254 97 99 10.1126/science.1925564 1925564 (Pubitemid 21917324)
13. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, Goate A, Rossor M, Roques P, Hardy J, Nature 1991 353 844 846 10.1038/353844a0 1944558 (Pubitemid 21912637)
14. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, Nature 1992 359 322 325 10.1038/359322a0 1383826
15. Role of the familial Dutch mutation E22Q in the folding and aggregation of the 15-28 fragment of the Alzheimer amyloid-beta protein. Baumketner A, Krone MG, Shea JE, Proc Natl Acad Sci USA 2008 105 6027 6032 10.1073/pnas.0708193105 18408165 (Pubitemid 351758393)
16. Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, Frangione B, Ghiso J, J Biol Chem 2000 275 27110 27116 10821838
17. Familial Alzheimer's disease mutations alter the stability of the amyloid beta-protein monomer folding nucleus. Grant MA, Lazo ND, Lomakin A, Condron MM, Arai H, Yamin G, Rigby AC, Teplow DB, Proc Natl Acad Sci USA 2007 104 16522 16527 10.1073/pnas.0705197104 17940047 (Pubitemid 350211051)
18. On the nucleation of amyloid beta-protein monomer folding. Lazo ND, Grant MA, Condron MC, Rigby AC, Teplow DB, Protein Sci 2005 14 1581 1596 15930005 (Pubitemid 41007920)
19. Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. Davis J, Van Nostrand WE, Proc Natl Acad Sci USA 1996 93 2996 3000 10.1073/pnas.93.7.2996 8610157 (Pubitemid 26114352)
20. Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. Murakami K, Irie K, Morimoto A, Ohigashi H, Shindo M, Nagao M, Shimizu T, Shirasawa T, J Biol Chem 2003 278 46179 46187 10.1074/jbc.M301874200 12944403 (Pubitemid 37432769)
21. Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. Morelli L, Llovera R, Gonzalez SA, Affranchino JL, Prelli F, Frangione B, Ghiso J, Castano EM, J Biol Chem 2003 278 23221 23226 10.1074/jbc.M300276200 12695513 (Pubitemid 36830134)
22. E22Q-mutant Abeta peptide (AbetaDutch) increases vascular but reduces parenchymal Abeta deposition. Herzig MC, Eisele YS, Staufenbiel M, Jucker M, Am J Pathol 2009 174 722 726 10.2353/ajpath.2009.080790 19218342
23. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. De Jonghe C, Zehr C, Yager D, Prada CM, Younkin S, Hendriks L, Van BC, Eckman CB, Neurobiol Dis 1998 5 281 286 10.1006/nbdi.1998.0202 9848098 (Pubitemid 28519158)
24. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. Haass C, Hung AY, Selkoe DJ, Teplow DB, J Biol Chem 1994 269 17741 17748 8021287
25. An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production. Tian Y, Bassit B, Chau D, Li YM, Nat Struct Mol Biol 2010 17 151 158 10.1038/nsmb.1743 20062056
26. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Näslund J, Lannfelt L, Nat Neurosci 2001 4 887 893 10.1038/nn0901-887 11528419 (Pubitemid 32801591)
27. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H, Ann Neurol 2008 63 377 387 10.1002/ana.21321 18300294 (Pubitemid 351499867)
28. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Naslund J, Axelman K, Bird TD, Nochlin D, Schellenberg GD, Wahlund LO, Lannfelt L, Arch Neurol 2008 65 499 505 10.1001/archneur.65.4.499 18413473 (Pubitemid 351549959)
29. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Stürchler-Pierrat C, Bürki K, van Duinen SG, Maat-Schieman ML, Staufenbiel M, Mathews PM, Jucker M, Nat Neurosci 2004 7 954 960 10.1038/nn1302 15311281 (Pubitemid 39129504)
30. A mouse model of amyloid {beta} oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H, J Neurosci 2010 30 4845 4856 10.1523/JNEUROSCI.5825-09. 2010 20371804
31. Structural dynamics of the DeltaE22 (Osaka) familial Alzheimer's disease-linked amyloid beta-protein. Inayathullah M, Teplow DB, Amyloid 2011 18 98 107 21838450
32. The Osaka FAD mutation E22Delta leads to the formation of a previously unknown type of amyloid beta fibrils and modulates Abeta neurotoxicity. Ovchinnikova OY, Finder VH, Vodopivec I, Nitsch RM, Glockshuber R, J Mol Biol 2011 408 780 791 10.1016/j.jmb.2011.02.049 21402079
33. The Japanese mutant Abeta (DeltaE22-Abeta(1-39)) forms fibrils instantaneously, with low-thioflavin T fluorescence: seeding of wild-type Abeta(1-40) into atypical fibrils by DeltaE22-Abeta(1-39). Cloe AL, Orgel JP, Sachleben JR, Tycko R, Meredith SC, Biochemistry 2011 50 2026 2039 10.1021/bi1016217 21291268
34. Pathologic amyloid beta-protein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. Van Nostrand WE, Melchor JP, Ruffini L, J Neurochem 1998 70 216 223 9422365 (Pubitemid 28020846)
35. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Cai XD, Golde TE, Younkin SG, Science 1993 259 514 516 10.1126/science.8424174 8424174 (Pubitemid 23058708)
36. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ, Nature 1992 360 672 674 10.1038/360672a0 1465129 (Pubitemid 23007680)
37. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, Winblad B, Venizelos N, Lannfelt L, Selkoe DJ, Proc Natl Acad Sci USA 1994 91 11993 11997 10.1073/pnas.91.25.11993 7991571 (Pubitemid 24368590)
38. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L, Nat Genet 1992 1 345 347 10.1038/ng0892-345 1302033
39. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J, Proc Natl Acad Sci USA 2000 97 1456 1460 10.1073/pnas.97.4.1456 10677483 (Pubitemid 30118462)
40. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M, Science 1999 286 735 741 10.1126/science.286.5440.735 10531052 (Pubitemid 29505878)
41. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. Koo EH, Squazzo SL, J Biol Chem 1994 269 17386 17389 8021238 (Pubitemid 24218009)
42. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ, Nat Med 1995 1 1291 1296 10.1038/nm1295-1291 7489411
43. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S, Davis JB, J Neurochem 2007 100 802 809 10.1111/j.1471-4159.2006.04260.x 17156133 (Pubitemid 46095629)
44. A therapeutic antibody targeting BACE1 inhibits amyloid-{beta} production in vivo. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise CE, Hoyte K, Luk W, Lu Y, Peng K, Wu P, Rouge L, Zhang Y, Lazarus RA, Scearce-Levie K, Wang W, Wu Y, Tessier-Lavigne M, Watts RJ, Sci Transl Med 2011 3 84ra43 10.1126/scitranslmed.3002254 21613622
45. APP intracellular domain formation and unaltered signaling in the presence of familial Alzheimer's disease mutations. Bergman A, Religa D, Karlstrom H, Laudon H, Winblad B, Lannfelt L, Lundkvist J, Naslund J, Exp Cell Res 2003 287 1 9 10.1016/S0014-4827(03)00117-4 12799176 (Pubitemid 36683195)
46. Mutations in APP have independent effects on Abeta and CTFgamma generation. Hecimovic S, Wang J, Dolios G, Martinez M, Wang R, Goate AM, Neurobiol Dis 2004 17 205 218 10.1016/j.nbd.2004.04.018 15474359 (Pubitemid 39345777)
47. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, Golde TE, Younkin SG, Science 1994 264 1336 1340 10.1126/science.8191290 8191290
48. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T, Neuron 2005 47 191 199 10.1016/j.neuron.2005.06.030 16039562 (Pubitemid 41019251)
49. Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch. Gu Y, Misonou H, Sato T, Dohmae N, Takio K, Ihara Y, J Biol Chem 2001 276 35235 35238 10.1074/jbc.C100357200 11483588
50. {gamma}-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of {beta}-carboxyl terminal fragment. Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y, J Neurosci 2009 29 13042 13052 10.1523/JNEUROSCI.2362-09.2009 19828817
51. Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Lichtenthaler SF, Wang R, Grimm H, Uljon SN, Masters CL, Beyreuther K, Proc Natl Acad Sci USA 1999 96 3053 3058 10.1073/pnas.96.6.3053 10077635 (Pubitemid 29148842)
52. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, Perkicak-Vance MA, Tanzi RE, Roses AD, et al. Nature 1995 375 754 760 10.1038/375754a0 7596406
53. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Levylahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al. Science 1995 269 973 977 10.1126/science.7638622 7638622
54. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al. Nature 1995 376 775 778 10.1038/376775a0 7651536
55. Alzheimer Disease and Frontotemporal Dementia Mutation Database. http://www.molgen.ua.ac.be/ADMutations
56. Alzheimer Research Forum: The Presenilin-1 Mutations. http://www.alzforum.org/res/com/mut/pre/table1.asp
57. Presenilin-dependent receptor processing is required for axon guidance. Bai G, Chivatakarn O, Bonanomi D, Lettieri K, Franco L, Xia C, Stein E, Ma L, Lewcock JW, Pfaff SL, Cell 2011 144 106 118 10.1016/j.cell.2010.11.053 21215373
58. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Sardi SP, Murtie J, Koirala S, Patten BA, Corfas G, Cell 2006 127 185 197 10.1016/j.cell.2006.07.037 17018285 (Pubitemid 44466644)
59. Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. Esselens C, Oorschot V, Baert V, Raemaekers T, Spittaels K, Serneels L, Zheng H, Saftig P, De Strooper B, Klumperman J, Annaert W, J Cell Biol 2004 166 1041 1054 10.1083/jcb.200406060 15452145 (Pubitemid 39304767)
60. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by alzheimer-related PS1 mutations. Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA, Cell 2010 141 1146 1158 10.1016/j.cell.2010.05.008 20541250
61. ER calcium and Alzheimer's disease: in a state of flux. Mattson MP, Sci Signal 2010 3 e10 10.1126/scisignal.3114pe10 20332425
62. Presenilin diversifies its portfolio. Parks AL, Curtis D, Trends Genet 2007 23 140 150 10.1016/j.tig.2007.01.008 17280736 (Pubitemid 46275145)
63. Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. Thinakaran G, Harris CL, Ratovitski T, Davenport F, Slunt HH, Price DL, Borchelt DR, Sisodia SS, J Biol Chem 1997 272 28415 28422 10.1074/jbc.272.45.28415 9353300 (Pubitemid 27517788)
64. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H, De Strooper B, J Neurochem 2006 96 732 742 10.1111/j.1471-4159.2005.03578.x 16405513
65. Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. Walker ES, Martinez M, Brunkan AL, Goate A, J Neurochem 2005 92 294 301 10.1111/j.1471-4159.2004. 02858.x 15663477 (Pubitemid 40194020)
66. FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. Flood DG, Reaume AG, Dorfman KS, Lin YG, Lang DM, Trusko SP, Savage MJ, Annaert WG, De Strooper B, Siman R, Scott RW, Neurobiol Aging 2002 23 335 348 10.1016/S0197-4580(01)00330-X 11959395 (Pubitemid 34312016)
67. Accumulation of murine amyloidbeta42 in a gene-dosage-dependent manner in PS1 'knock-in' mice. Nakano Y, Kondoh G, Kudo T, Imaizumi K, Kato M, Miyazaki JI, Tohyama M, Takeda J, Takeda M, Eur J Neurosci 1999 11 2577 2581 10.1046/j.1460-9568.1999.00698.x 10383647 (Pubitemid 29292352)
68. Potent amyloidogenicity and pathogenicity of Abeta43. Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson P, Takano J, Nishimura M, Iwata N, Van Broeckhoven C, Ihara Y, Saido TC, Nat Neurosci 2011 14 1023 1032 10.1038/nn.2858 21725313
69. Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. Wang R, Wang B, He W, Zheng H, J Biol Chem 2006 281 15330 15336 10.1074/jbc.M512574200 16574645 (Pubitemid 43855123)
70. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimers disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimers disease. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S, Nat Med 1996 2 864 869 10.1038/nm0896-864 8705854 (Pubitemid 26296755)
71. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. De Strooper B, EMBO Rep 2007 8 141 146 10.1038/sj.embor.7400897 17268505 (Pubitemid 46420841)
72. The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism. Shen J, Kelleher RJ, Proc Natl Acad Sci USA 2007 104 403 409 10.1073/pnas.0608332104 17197420 (Pubitemid 46123039)
73. When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. Wolfe MS, EMBO Rep 2007 8 136 140 10.1038/sj.embor.7400896 17268504 (Pubitemid 46420840)
74. Mutant presenilins of Alzheimer's disease increase production of 42- residue amyloid beta-protein in both transfected cells and transgenic mice. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ, Nat Med 1997 3 67 72 10.1038/nm0197-67 8986743 (Pubitemid 27019143)
75. Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner BA, Proc Natl Acad Sci USA 1999 96 6959 6963 10.1073/pnas.96.12.6959 10359821 (Pubitemid 29274992)
76. Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signalling independently of proteolytic processing. Baumeister R, Leimer U, Zweckbronner I, Jakubek C, Grunberg J, Haass C, Genes Funct 1997 1 149 159 10.1046/j.1365-4624.1997.00012.x 9680315
77. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Levitan D, Doyle TG, Brousseau D, Lee MK, Thinakaran G, Slunt HH, Sisodia SS, Greenwald I, Proc Natl Acad Sci USA 1996 93 14940 14944 10.1073/pnas.93.25.14940 8962160 (Pubitemid 26419074)
78. Presenilin 1 mutations activate gamma 42-secretase but reciprocally inhibit epsilon-secretase cleavage of amyloid precursor protein (APP) and S3-cleavage of notch. Chen F, Gu Y, Hasegawa H, Ruan X, Arawaka S, Fraser P, Westaway D, Mount H, St George-Hyslop P, J Biol Chem 2002 277 36521 36526 10.1074/jbc.M205093200 12119298
79. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, Robakis NK, Cell 2003 114 635 645 10.1016/j.cell.2003.08.008 13678586 (Pubitemid 37159259)
80. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, Kaether C, Zheng H, Ghetti B, Haass C, Steiner H, Proc Natl Acad Sci USA 2002 99 8025 8030 10.1073/pnas.112686799 12048239 (Pubitemid 34650999)
81. Notch-1 activation by familial Alzheimer's disease (FAD)-linked mutant forms of presenilin-1. Nakajima M, Shimizu T, Shirasawa T, J Neurosci Res 2000 62 311 317 10.1002/1097-4547(20001015)62:2<311::AID-JNR16>3.0.CO;2-G 11020224
82. Intramembrane proteolysis of GxGD-type aspartyl proteases is slowed by a familial Alzheimer disease-like mutation. Fluhrer R, Fukumori A, Martin L, Grammer G, Haug-Kröper M, Klier B, Winkler E, Kremmer E, Condron MM, Teplow DB, Steiner H, Haass C, J Biol Chem 2008 283 30121 30128 10.1074/jbc.M806092200 18768471
83. Distinct mechanisms by mutant presenilin 1 and 2 leading to increased intracellular levels of amyloid beta-protein 42 in Chinese hamster ovary cells. Qi Y, Morishima-Kawashima M, Sato T, Mitsumori R, Ihara Y, Biochemistry 2003 42 1042 1052 10.1021/bi0267590 12549925 (Pubitemid 36159538)
84. Enzymatic characteristics of I213T mutant presenilin-1/gamma-secretase in cell models and knock-in mouse brains: familial Alzheimer disease-linked mutation impairs gamma-site cleavage of amyloid precursor protein C-terminal fragment beta. Shimojo M, Sahara N, Mizoroki T, Funamoto S, Morishima-Kawashima M, Kudo T, Takeda M, Ihara Y, Ichinose H, Takashima A, J Biol Chem 2008 283 16488 16496 10.1074/jbc.M801279200 18430735
85. An Alzheimer's disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos. Davis JA, Naruse S, Chen H, Eckman C, Younkin S, Price DL, Borchelt DR, Sisodia SS, Wong PC, Neuron 1998 20 603 609 10.1016/S0896-6273(00)80998-8 9539132 (Pubitemid 28153088)
86. Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Abeta1-42/43 expression. Qian S, Jiang P, Guan XM, Singh G, Trumbauer ME, Yu H, Chen HY, Van de Ploeg LH, Zheng H, Neuron 1998 20 611 617 10.1016/S0896-6273(00)80999-X 9539133 (Pubitemid 28153089)
87. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, Liu C, Ibrahim S, Beran M, Zavadil J, Efstratiadis A, Taghon T, Michor F, Levine RL, Aifantis I, Nature 2011 473 230 233 10.1038/nature09999 21562564
88. Gamma-secretase gene mutations in familial acne inversa. Wang B, Yang W, Wen W, Sun J, Su B, Liu B, Ma D, Lv D, Wen Y, Qu T, Chen M, Sun M, Shen Y, Zhang X, Science 2010 330 1065 10.1126/science.1196284 20929727
89. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, Leigh IM, Collisson EA, Gordon PB, Jakkula L, Pennypacker S, Zou Y, Sharma M, North JP, Vemula SS, Mauro TM, Neuhaus IM, Leboit PE, Hur JS, Park K, Huh N, Kwok PY, Arron ST, Massion PP, Bale AE, Haussler D, Cleaver JE, Gray JW, Spellman PT, South AP, et al. Proc Natl Acad Sci USA 2011 108 17761 17766 10.1073/pnas.1114669108 22006338
90. Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. Li T, Wen H, Brayton C, Laird FM, Ma G, Peng S, Placanica L, Wu TC, Crain BJ, Price DL, Eberhart CG, Wong PC, J Neurosci 2007 27 10849 10859 10.1523/JNEUROSCI.2152-07.2007 17913918 (Pubitemid 47535873)
91. Wild-type but not FAD mutant presenilin-1 prevents neuronal degeneration by promoting phosphatidylinositol 3-kinase neuroprotective signaling. Baki L, Neve RL, Shao Z, Shioi J, Georgakopoulos A, Robakis NK, Neurosci 2008 28 483 490 10.1523/JNEUROSCI.4067-07.2008
92. Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling. Kang DE, Yoon IS, Repetto E, Busse T, Yermian N, Ie L, Koo EH, J Biol Chem 2005 280 31537 31547 10.1074/jbc.M500833200 16014629 (Pubitemid 41291897)
93. Formation of tau inclusions in knock-in mice with familial Alzheimer disease (FAD) mutation of presenilin 1 (PS1). Tanemura K, Chui DH, Fukuda T, Murayama M, Park JM, Akagi T, Tatebayashi Y, Miyasaka T, Kimura T, Hashikawa T, Nakano Y, Kudo T, Takeda M, Takashima A, J Biol Chem 2006 281 5037 5041 16377636 (Pubitemid 43847768)
94. Insensitivity to Abeta 42-lowering non-steroidal anti-inflammatory drugs (NSAIDs) and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. Czirr E, Leuchtenberger S, Dorner-Ciossek C, Schneider A, Jucker M, Koo EH, Pietrzik CU, Baumann K, Weggen S, J Biol Chem 2007 282 24504 24513 10.1074/jbc.M700618200 17573346 (Pubitemid 47347550)
95. Familial Alzheimer disease-linked presenilin 1 variants enhance production of both Abeta 1-40 and Abeta 1-42 peptides that are only partially sensitive to a potent aspartyl protease transition state inhibitor of "gamma-secretase". Ikeuchi T, Dolios G, Kim SH, Wang R, Sisodia SS, J Biol Chem 2003 278 7010 7018 10.1074/jbc.M209252200 12493731 (Pubitemid 36800696)
96. FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex. Xia W, Ostaszewski BL, Kimberly WT, Rahmati T, Moore CL, Wolfe MS, Selkoe DJ, Neurobiol Dis 2000 7 673 681 10.1006/nbdi.2000.0322 11114265 (Pubitemid 32044291)
97. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to gamma-secretase modulators regardless of their potency and structure. Hahn S, Bruning T, Ness J, Czirr E, Baches S, Gijsen H, Korth C, Pietrzik CU, Bulic B, Weggen S, J Neurochem 2011 116 385 395 10.1111/j.1471-4159.2010.07118.x 21091478
98. Generation of Abeta 38 and Abeta 42 is independently and differentially affected by FAD-associated presenilin 1 mutations and gamma -secretase modulation. Page RM, Baumann K, Tomioka M, Perez-Revuelta BI, Fukumori A, Jacobsen H, Flohr A, Luebbers T, Ozmen L, Steiner H, Haass C, J Biol Chem 2008 283 677 683 10.1074/jbc.M708754200 17962197
99. APP mutants respond to {gamma}-secretase modulators. Page RM, Gutsmiedl A, Fukumori A, Winkler E, Haass C, Steiner H, J Biol Chem 2010 285 17798 17810 10.1074/jbc.M110.103283 20348104
100. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH, J Biol Chem 2003 278 31831 31837 10.1074/jbc.M303592200 12805356 (Pubitemid 37048365)
101. Attenuated A{beta}42 responses to low potency {gamma}-secretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds. Kretner B, Fukumori A, Gutsmiedl A, Page RM, Luebbers T, Galley G, Baumann K, Haass C, Steiner H, J Biol Chem 2011 286 15240 15251 10.1074/jbc.M110.213587 21357415
102. The human brain in a dish: the promise of iPSC-derived neurons. Dolmetsch R, Geschwind DH, Cell 2011 145 831 834 10.1016/j.cell.2011.05.034 21663789
103. Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations. Soldner F, Laganière J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, Khurana V, Golbe LI, Myers RH, Lindquist S, Zhang L, Guschin D, Fong LK, Vu BJ, Meng X, Urnov FD, Rebar EJ, Gregory PD, Zhang HS, Jaenisch R, Cell 2011 146 318 331 10.1016/j.cell.2011.06.019 21757228
104. Recombinase-mediated cassette exchange (RMCE): traditional concepts and current challenges. Turan S, Galla M, Ernst E, Qiao J, Voelkel C, Schiedlmeier B, Zehe C, Bode J, J Mol Biol 2011 407 193 221 10.1016/j.jmb.2011.01.004 21241707
105. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, Mazzoleni G, Merlin M, Giovagnoli AR, Prioni S, Erbetta A, Falcone C, Gobbi M, Colombo L, Bastone A, Beeg M, Manzoni C, Francescucci B, Spagnoli A, Cant L, Del Favero E, Levy E, Salmona M, Tagliavini F, Science 2009 323 1473 1477 10.1126/science. 1168979 19286555
106. Early onset familial Alzheimer's disease: Mutation frequency in 31 families. Janssen JC, Beck JA, Campbell TA, Dickinson A, Fox NC, Harvey RJ, Houlden H, Rossor MN, Collinge J, Neurology 2003 60 235 239 12552037 (Pubitemid 36152015)
107. Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. Wakutani Y, Watanabe K, Adachi Y, Wada-Isoe K, Urakami K, Ninomiya H, Saido TC, Hashimoto T, Iwatsubo T, Nakashima K, J Neurol Neurosurg Psychiatry 2004 75 1039 1042 10.1136/jnnp.2003.010611 15201367 (Pubitemid 38869622)
108. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Hendriks L, van Duijn CM, Cras P, Cruts M, Van HW, van HF, Warren A, McInnis MG, Antonarakis SE, Martin JJ, Nat Genet 1992 1 218 221 10.1038/ng0692-218 1303239
109. Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. Bugiani O, Giaccone G, Rossi G, Mangieri M, Capobianco R, Morbin M, Mazzoleni G, Cupidi C, Marcon G, Giovagnoli A, Bizzi A, Di Fede G, Puoti G, Carella F, Salmaggi A, Romorini A, Patruno GM, Magoni M, Padovani A, Tagliavini F, Arch Neurol 2010 67 987 995 10.1001/archneurol.2010.178 20697050
110. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM, Ann Neurol 2001 49 697 705 10.1002/ana.1009 11409420 (Pubitemid 32530235)
111. A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Rossi G, Giaccone G, Maletta R, Morbin M, Capobianco R, Mangieri M, Giovagnoli AR, Bizzi A, Tomaino C, Perri M, Di Natale M, Tagliavini F, Bugiani O, Bruni AC, Neurology 2004 63 910 912 15365148 (Pubitemid 39297659)
112. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Kumar-Singh S, De Jonghe C, Cruts M, Kleinert R, Wang R, Mercken M, De Strooper B, Vanderstichele H, Löfgren A, Vanderhoeven I, Backhovens H, Vanmechelen E, Kroisel PM, Van Broeckhoven C, Hum Mol Genet 2000 9 2589 2598 10.1093/hmg/9.18.2589 11063718
113. An Iranian family with Alzheimer's disease caused by a novel APP mutation (Thr714Ala). Pasalar P, Najmabadi H, Noorian AR, Moghimi B, Jannati A, Soltanzadeh A, Krefft T, Crook R, Hardy J, Neurology 2002 58 1574 1575 12034808 (Pubitemid 34552978)
114. Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 - > Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease. Ancolio K, Dumanchin C, Barelli H, Warter JM, Brice A, Campion D, Frebourg T, Checler F, Proc Natl Acad Sci USA 1999 96 4119 4124 10.1073/pnas.96.7.4119 10097173 (Pubitemid 29169046)
115. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. De Jonghe C, Esselens C, Kumar-Singh S, Craessaerts K, Serneels S, Checler F, Annaert W, Van BC, De SB, Hum Mol Genet 2001 10 1665 1671 10.1093/hmg/10.16.1665 11487570 (Pubitemid 32776296)
116. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Eckman CB, Mehta ND, Crook R, Perez-tur J, Prihar G, Pfeiffer E, Graff-Radford N, Hinder P, Yager D, Zenk B, Refolo LM, Prada CM, Younkin SG, Hutton M, Hardy J, Hum Mol Genet 1997 6 2087 2089 10.1093/hmg/6.12.2087 9328472 (Pubitemid 27477950)
117. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Guerreiro RJ, Baquero M, Blesa R, Boada M, Brás JM, Bullido MJ, Calado A, Crook R, Ferreira C, Frank A, Gámez-Isla T, Hernández I, Lleá A, Machado A, Martínez-Lage P, Masdeu J, Molina-Porcel L, Molinuevo JL, Pastor P, Pérez-Tur J, Relvas R, Oliveira CR, Ribeiro MH, Rogaeva E, Sa A, Samaranch L, Sánchez-Valle R, Santana I, Trraga L, Valdivieso F, et al. Neurobiol Aging 2010 31 725 731 10.1016/j.neurobiolaging.2008.06.012 18667258
118. Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene. Murrell JR, Hake AM, Quaid KA, Farlow MR, Ghetti B, Arch Neurol 2000 57 885 887 10.1001/archneur.57.6.885 10867787 (Pubitemid 30397192)
119. Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides. Ghidoni R, Albertini V, Squitti R, Paterlini A, Bruno A, Bernardini S, Cassetta E, Rossini PM, Squitieri F, Benussi L, Binetti G, J Alzheimers Dis 2009 18 295 303 19584443
120. Novel Leu723Pro amyloid precursor protein mutation increases amyloid beta42(43) peptide levels and induces apoptosis. Kwok JB, Li QX, Hallupp M, Whyte S, Ames D, Beyreuther K, Masters CL, Schofi eld PR, Ann Neurol 2000 47 249 253 10.1002/1531-8249(200002)47:2<249::AID-ANA18>3.0.CO;2-8 10665499 (Pubitemid 30078575)
121. Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Theuns J, Marjaux E, Vandenbulcke M, Van Laere K, Kumar-Singh S, Bormans G, Brouwers N, Van den Broeck M, Vennekens K, Corsmit E, Cruts M, De Strooper B, Van Broeckhoven C, Vandenberghe R, Hum Mutat 2006 27 888 896 10.1002/humu.20402 16917905 (Pubitemid 44336938)
122. APP substitutions V715F and L720P alter PS1 conformation and differentially affect Abeta and AICD generation. Tesco G, Ginestroni A, Hiltunen M, Kim M, Dolios G, Hyman BT, Wang R, Berezovska O, Tanzi RE, J Neurochem 2005 95 446 456 10.1111/j.1471-4159.2005.03381.x 16086682 (Pubitemid 41457513)
123. Decreased Abeta secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1. Shimojo M, Sahara N, Murayama M, Ichinose H, Takashima A, Neurosci Res 2007 57 446 453 10.1016/j.neures.2006.12.005 17210196 (Pubitemid 46283080)
124. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR, Hum Mol Genet 2004 13 159 170 14645205 (Pubitemid 38111354)
125. Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Qiang L, Fujita R, Yamashita T, Angulo S, Rhinn H, Rhee D, Doege C, Chau L, Aubry L, Vanti WB, Moreno H, Abeliovich A, Cell 2011 146 359 371 10.1016/j.cell.2011.07.007 21816272
126. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, Capell A, Walter J, Grünberg J, Haass C, Iwatsubo T, Obata K, Proc Natl Acad Sci USA 1997 94 2025 2030 10.1073/pnas.94.5.2025 9050898 (Pubitemid 27113955)
127. Dissociated phenotypes in presenilin transgenic mice define functionally distinct gamma-secretases. Mastrangelo P, Mathews PM, Chishti MA, Schmidt SD, Gu Y, Yang J, Mazzella MJ, Coomaraswamy J, Horne P, Strome B, Pelly H, Levesque G, Ebeling C, Jiang Y, Nixon RA, Rozmahel R, Fraser PE, St George-Hyslop P, Carlson GA, Westaway D, Proc Natl Acad Sci USA 2005 102 8972 8977 10.1073/pnas.0500940102 15951428 (Pubitemid 40881063)
128. Mutant presenilin 2 transgenic mice. A large increase in the levels of Abeta 42 is presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin. Sawamura N, Morishima-Kawashima M, Waki H, Kobayashi K, Kuramochi T, Frosch MP, Ding K, Ito M, Kim TW, Tanzi RE, Oyama F, Tabira T, Ando S, Ihara Y, J Biol Chem 2000 275 27901 27908 10846187